U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 53 results

Status:
US Approved Rx (2024)
First approved in 2001

Class (Stereo):
CHEMICAL (ABSOLUTE)



Galantamine (RAZADYNE®, galantamine hydrobromide) is a benzazepine derived from norbelladine. It is found in Galanthus and other Amaryllidaceae. It is a reversible, competitive acetylcholinesterase inhibitor that is used for the treatment of mild to ...
Status:
US Approved Rx (2018)
First approved in 2000

Class (Stereo):
CHEMICAL (ABSOLUTE)



Rivastigmine (sold under the trade name Exelon) is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease. Rivastigmine, an acetylcholinesterase inhibi...
Status:
US Approved Rx (2016)
First approved in 1996

Class (Stereo):
CHEMICAL (RACEMIC)



Donepezil, marketed under the trade name Aricept, is a medication used in the palliative treatment of Alzheimer's disease. Aricept is indicated for the treatment of dementia of the Alzheimer’s type. Efficacy has been demonstrated in patients with mil...
Status:
US Approved Rx (1973)
First approved in 1955

Class (Stereo):
CHEMICAL (ACHIRAL)



Acquired myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction, characterized clinically by muscle weakness and abnormal fatigability on exertion. Current guidelines and recommendations for MG treatment are based large...
Status:
US Approved Rx (2021)
First marketed in 1931

Class (Stereo):
CHEMICAL (ACHIRAL)



Neostigmine is a cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. By inhi...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)

LADOSTIGIL, a rasagiline derivative, is a reversible acetylcholinesterase and butyrylcholinesterase inhibitor with neuroprotective properties. It also acts as an irreversible brain monoamine oxidases inhibitor. It is under development for the treatme...
Status:
Investigational

Class (Stereo):
CHEMICAL (RACEMIC)

Suronacrine (also known as HP128) is a tetrahydroacridinol derivative patented by Hoechst-Roussel Pharmaceuticals, Inc for the treatment of various memory dysfunctions characterized by decreased cholinergic function. The activity ofHP128 is attributa...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)

Icopezil (previously known as CP-118,954) was developed as a selective acetylcholinesterase inhibitor for the treatment of cognitive disorders. Phase II trials of icopezil were underway in Japan and in the USA for the treatment of patients with Alzhe...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)

Ganstigmine is an orally active, carbamate-based acetylcholinesterase (AChE) inhibitor developed for the treatment of Alzheimer's disease. It is a newer generation AChE than BChE inhibitor, derived from genserine, and has a long duration of action in...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)

Quilostigmine (also known as NXX-066) is an isoquinolinecarboxylate patented by Hoechst-Roussel Pharmaceuticals Inc as a memory enhancer. Quilostigmine acts as acetylcholinesterase inhibitor and studies as a potential drug for treating Alzheimer’s di...